Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 13/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165155 | 0.82 | PTGS1 (0.45) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL3165162 | 0.82 | PTGS1 (0.45) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL4627757 | 0.81 | PTGS1 (0.47) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL4627759 | 0.81 | PTGS1 (0.47) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL13991504 | 0.77 | PTGS1 (0.44) | PTGS1PTGS2F10F2KLKB1 | |
| SCHEMBL4392175 | 0.73 | PTPN1 (0.49) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL4392170 | 0.73 | PTPN1 (0.49) | PTGS1PTGS2F10MAOAMAOB | |
| SCHEMBL4932684 | 0.71 | F10 (0.43) | PTGS1PTGS2F10 | |
| SCHEMBL4932690 | 0.71 | F10 (0.43) | PTGS1PTGS2F10 | |
| SCHEMBL4061262 | 0.69 | PTGS1 (0.43) | PTGS1PTGS2MAOAMAOBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1567519-B1 | CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE | GLAXO GROUP LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2004052878-A2 | CRYSTALLINE DERIVATIVE OF 2- (5-CHLOROTHIEN-2-YL)-N- ((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL) ETHENSULFONAMIDE | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052851-A1 | PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | PTGS1 53/4885PTGS2 80/4885F10 192/4885 |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | PTGS1 741/4885PTGS2 1284/4885F10 11/4885 |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | TFPI, TPSAB1, TFPI2 | PTGS1 953/4885PTGS2 1929/4885F10 24/4885 |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | PTGS1 466/4885PTGS2 819/4885F10 472/4885 |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | PTGS1 466/4885PTGS2 819/4885F10 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.